Hodgkin Lymphoma Latest Advances

Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study.

Journal: Leukemia & lymphoma

Published: April 10, 2026

Targeted therapy in early-stage classical Hodgkin lymphoma.

Journal: Blood

Published: April 09, 2026

Persistent 18F-FDG Uptake in a Post-treatment Hodgkin's Lymphoma: Not Always Residual Disease.

Journal: Molecular imaging and radionuclide therapy

Published: April 08, 2026

The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review.

Journal: Expert review of hematology

Published: April 04, 2026

Hodgkinoid histiocytosis, a distinctive histiocytic/dendritic cell disorder clinically mimicking drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: April 01, 2026

Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms.

Journal: International journal of surgical pathology

Published: April 01, 2026

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Journal: International journal of surgical pathology

Published: April 01, 2026

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.

Journal: Journal for immunotherapy of cancer

Published: March 30, 2026

Eosinophilic, polymorphic, and pruritic eruption associated with radiation treated with dupilumab in a patient with Hodgkin lymphoma.

Journal: JAAD case reports

Published: March 30, 2026

A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling.

Journal: bioRxiv : the preprint server for biology

Published: March 27, 2026

Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.

Journal: Blood

Published: March 26, 2026

Allogeneic Hematopoietic Cell Transplantation for Relapsed / Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: March 26, 2026

Hodgkin Lymphoma Latest Advances

Find the Latest Research About Hodgkin Lymphoma

Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study.

Treatment choice for chronic lymphocytic leukemia after covalent BTKi therapy: a patient and oncologist preference study.

Targeted therapy in early-stage classical Hodgkin lymphoma.

Targeted therapy in early-stage classical Hodgkin lymphoma.

Persistent 18F-FDG Uptake in a Post-treatment Hodgkin's Lymphoma: Not Always Residual Disease.

Persistent 18F-FDG Uptake in a Post-treatment Hodgkin's Lymphoma: Not Always Residual Disease.

The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review.

The molecular pathogenesis of Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a scoping review.

Hodgkinoid histiocytosis, a distinctive histiocytic/dendritic cell disorder clinically mimicking drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.

Hodgkinoid histiocytosis, a distinctive histiocytic/dendritic cell disorder clinically mimicking drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.

Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms.

Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms.

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.

Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.

Eosinophilic, polymorphic, and pruritic eruption associated with radiation treated with dupilumab in a patient with Hodgkin lymphoma.

Eosinophilic, polymorphic, and pruritic eruption associated with radiation treated with dupilumab in a patient with Hodgkin lymphoma.

A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling.

A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling.

Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.

Jaye DL, Feldman AL. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma. Blood. 2023;141(17):2160.

Allogeneic Hematopoietic Cell Transplantation for Relapsed / Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience.

Allogeneic Hematopoietic Cell Transplantation for Relapsed / Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience.